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E-mail address: adele.lehane@anu.edu.au (A.M. LeChloroquine (CQ) was once a very effective antimalarial drug that, at its peak, was consumed in the hun-
dreds of millions of doses per year. The drug acts against the Plasmodium parasite during the asexual
intra-erythrocytic phase of its lifecycle. Unfortunately, clinical resistance to this drug is now widespread.
Questions remain about precisely how CQ kills malaria parasites, and by what means some CQ-resistant
(CQR) parasites can withstand much higher concentrations of the drug than others that also fall in the
CQR category. In this review we investigate the evidence for and against the proposal that CQ kills par-
asites by generating oxidative stress. Further, we examine a long-held idea that the glutathione system of
malaria parasites plays a role in CQ resistance. We conclude that there is strong evidence that glutathione
levels modulate CQ response in the rodent malaria species Plasmodium berghei, but that a role for redox in
contributing to the degree of CQ resistance in species infectious to humans has not been ﬁrmly
established.
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Open ac1. Introduction
The deadliest malaria parasite of humans, Plasmodium falcipa-
rum, must acquire and digest haemoglobin (Hb) from the host
erythrocyte in order to survive. Hb digestion takes place within
the parasite’s internal digestive vacuole (DV), and results in the
generation of large quantities of potentially toxic haem moieties.cess under CC BY-NC-ND license.
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in the DV.
P. falciparum parasites resistant to CQ emerged in the late 1950s,
and throughout the remainder of the 20th century spread from a
handful of founder locations to nearly every malaria-endemic
region of the world (Wootton et al., 2002; Volkman et al., 2007).
The primary determinant of CQ resistance in P. falciparum is muta-
tions in the Chloroquine Resistance Transporter (PfCRT) (Fidock
et al., 2000), a 49 kDa protein with 10 predicted transmembrane
domains that resides in the membrane bounding the parasite’s
DV (Fidock et al., 2000; Cooper et al., 2002). The weak-base nature
of CQ results in the ‘trapping’ of the charged, protonated form of
the drug in the acidic DV, and its accumulation therein to high con-
centrations. CQ-resistance-conferring mutations in PfCRT modify
the substrate speciﬁcity of the protein such that it facilitates the es-
cape of CQ, probably in its predominant diprotonated form, from
the DV (Martin et al., 2009). This reduces the concentration of the
drug at its site of action.2. Chloroquine resistance – what determines the level?
Of the numerous mutations that occur in PfCRT, which occur as
region-speciﬁc haplotypes, the K76T mutation is ubiquitous to CQR
parasites. This mutation has been validated in multiple studies as a
highly sensitive marker for CQ treatment failure (i.e. almost all pa-
tients who fail CQ treatment are infected with PfCRTK76T-bearing
parasites) (Djimde et al., 2001; Picot et al., 2009). However, many
patients infected with PfCRTK76T-expressing parasites respond ade-
quately to CQ treatment (Wellems and Plowe, 2001). Pre-existing
immunity and factors that inﬂuence the CQ concentration reached
in the plasma most likely aid in the cure of some patients infected
with PfCRTK76T-expressing parasites (Wellems and Plowe, 2001;
Djimde et al., 2003). Parasite-associated factors that together
determine the degree of mutant-PfCRT-mediated CQ resistance
are also likely to play a role.
In ﬁeld isolates, the K76T mutation is never found in isolation,
and to date 16 variant residues have been identiﬁed in CQ-resis-
tance-conferring forms of PfCRT (Ecker et al., in press). As a conse-
quence, there are many different isoforms of the protein, and it is
likely that these would be associated with different levels of sus-
ceptibility to CQ. To date, only two naturally occurring mutant
forms of PfCRT (those expressed by the Southeast Asian Dd2 strain
and the South American 7G8 strain) have been investigated in het-
erologous expression systems (Martin et al., 2009; Baro et al.,
2011). Furthermore, the Dd2 and 7G8 alleles are, to date, the only
natural variants for which data have been published on their ef-
fects on parasite drug response in the same genetic background
(Sidhu et al., 2002). Recent studies on pfcrt variants from Southeast
Asia and the Western Paciﬁc conﬁrm that distinct alleles can medi-
ate substantially different degrees of reduced CQ susceptibility
(Petersen and Fidock, in preparation).
There is ample evidence that the genetic background of a para-
site also plays an important role in determining the level of CQ
resistance imparted by mutant pfcrt. A study of the CQ susceptibil-
ity of those progeny of a genetic cross (between Dd2 and HB3) that
had inherited the mutant Dd2 pfcrt allele revealed CQ IC90 values
(i.e. the concentration of CQ required to inhibit parasite prolifera-
tion by 90%) ranging from 444 to 1141 nM (Ferdig et al., 2004).
Mutations in another DVmembrane-localised transporter, P-glyco-
protein homologue 1 (Pgh1; encoded by pfmdr1), appear to modu-
late CQ response in some but not all genetic backgrounds (Reed
et al., 2000; Sidhu et al., 2005; Sa et al., 2009; Patel et al., 2010).
However, it is clear that parasites with identical pfcrt and pfmdr1
alleles can also vary considerably in their CQ responses (Chen
et al., 2002; Ferdig et al., 2004; Sa et al., 2009). A recent transfec-tion study in which wild-type pfcrt was replaced with the mutant
7G8 allele in three different CQ-sensitive (CQS) strains of P. falcipa-
rum provided direct evidence that the genetic background of a
strain inﬂuences the extent to which mutant PfCRT affects CQ re-
sponse (Valderramos et al., 2010).
The search for secondary determinants of CQ resistance has pro-
ven challenging. With the exception of pfmdr1, other genes poten-
tially involved have thus far escaped detection (Mu et al., 2010),
suggesting that the individual contributions of other CQ-
response-modulating genes may be limited. A search for single
nucleotide polymorphisms (SNPs) in predicted or known trans-
porter proteins in 97 culture-adapted isolates (Mu et al., 2003)
led to the identiﬁcation of the P. falciparum Multidrug Resistance-
Associated Protein homologue (PfMRP) as a potential secondary
determinant of CQ resistance. PfMRP is, like Pgh1, a member of
the ATP-binding Cassette (ABC) superfamily of transporter proteins.
Two subsequent studies failed to conﬁrm an association between
mutations in PfMRP and CQ response (Anderson et al., 2005; Cojean
et al., 2006). However, a study in which PfMRP was disrupted in the
CQRW2 strain lent some support to the notion that PfMRPmay play
a role in CQ susceptibility, as the PfMRP knockout parasites
accumulated more CQ than the parental strain and were rendered
somewhat more susceptible to the drug (Raj et al., 2009).
A separate line of investigation involving a number of biochem-
ical studies has implicated elements of the redox system in inﬂu-
encing parasite susceptibility to CQ. In the following sections we
explore the hypothesis that differences in antioxidant power be-
tween different CQR strains of P. falciparum contribute to their
varying degrees of CQ resistance. Variation in antioxidant power
between parasite strains could arise from a number of distinct
mechanisms, potentially complicating efforts to identify redox
genes that could serve as secondary determinants of CQ resistance.3. Haemoglobin digestion in the malaria parasite – an oxidative
burden
In most eukaryotic cells, the mitochondrial electron transport
chain is responsible in large part for the cell’s oxidative burden. Re-
dox centres in this chain can ‘leak’ electrons to O2, resulting in the
formation of reactive oxygen species (ROS) (Turrens, 2003). In the
case of the malaria parasite, its intra-erythrocytic lifestyle has im-
parted an additional oxidative burden, arising from the digestion of
the majority of the host cell’s 5 mM Hb (each molecule of which
has four haem groups) as the parasite grows within the infected
cell. Hb degradation occurs in large part, if not entirely, within
the parasite’s DV (Klonis et al., 2007).
Hb digestion is essential for the parasite, providing it with ami-
no acids for protein synthesis, creating space for its growth, and
aiding the osmotic stability of the host cell (Lew et al., 2003; Gold-
berg, 2005). Hb digestion liberates toxic haem moieties, each of
which contains an iron atom chelated in the centre of a porphyrin
ring. In the acidic environment of the DV, the haem in oxyHb is oxi-
dised from the Fe2+ to the Fe3+ state. This is accompanied by the
production of O2 , which in the acidic DV is thought to dismutate
spontaneously to H2O2 and O2 (Becker et al., 2004). The parasite
must destroy or neutralise the haem and H2O2, as both species give
rise to a variety of toxic effects through their oxidation of biomol-
ecules, and in the case of haem, through additional non-oxidative
mechanisms (Fitch, 2004).3.1. Oxidative stress and the parasite’s mechanisms for dealing with
haem
The majority of the haem released in the parasite DV is thought
to be sequestered into haemozoin (Hz) (Egan, 2008), an apparently
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tin’’) dimers linked by hydrogen bonds (Pagola et al., 2000). How-
ever, one process may not be sufﬁcient to neutralise completely
the vast quantities of haem produced in the DV, and even if a small
percentage of the haem were to escape incorporation into Hz this
could give rise to a concentration that would be toxic to the para-
site (Becker et al., 2004). The parasite may therefore have addi-
tional mechanisms of haem detoxiﬁcation (Fig. 1). A number of
parasite proteins have been reported to bind haem (Choi et al.,
1999; Harwaldt et al., 2002; Campanale et al., 2003), but most of
these proteins might also be inhibited by haem, making it difﬁcult
to discern whether this binding is a protective mechanism or an
additional source of toxicity (Muller, 2004).
In addition to Hz formation and haem sequestration by protein
binding, twomechanisms by which haemmight be degraded in the
parasite have been described: glutathione-mediated degradation
(Atamna and Ginsburg, 1995) and peroxidative decomposition
(Loria et al., 1999). Both of these processes ultimately result in
the release of iron from haem. Current experimental methods have
precluded an unambiguous determination of the oxidation state of
the released iron. However, irrespective of its oxidation state the
liberated iron, in the presence of ROS, would almost certainly in-
duce oxidative damage by participating in the Fenton reaction
(Eq. (1)) or in the Haber–Weiss reaction (Eq. (2)), in which Fe3+ is
reduced to Fe2+ so it can then participate in Fenton chemistry
(Eq. (1)) (Liochev and Fridovich, 2002), resulting in the generation
of hydroxyl radicals (OH).
Fe2þ þH2O2 ! Fe3þ þ OHþ OH ð1ÞFe3þ þ O2 ! Fe2þ þ O2 ð2Þ
Hydroxyl radicals are highly reactive and in vivo often react
close to their site of formation. Within the DV, the production of
OH would lead rapidly to the inactivation of proteins and to mem-
brane damage by lipid peroxidation. Fenton chemistry is also espe-
cially damaging in vivowhere iron levels are elevated, as is the case
in the DV of the parasite. In environments such as this ongoing
Fenton chemistry can be propagated by the release of additional
iron from haem and its breakdown products. As a consequence,Fig. 1. Possible mechanisms of haem toxicity and neutralisation in malaria
parasites, and the proposed effect of chloroquine on these processes. GSH, reduced
glutathione.maintaining a favourable redox environment is likely to present
a constant challenge for the parasite, even when not under chemo-
therapeutic attack.4. Does chloroquine increase oxidative stress in the parasite?
CQ accumulates to high concentrations in the DV of the parasite
through a combination of weak-base trapping and binding to
haem, and the DV is thought to be its primary site of action (Fitch,
2004). The binding of CQ to haem has been reported to inhibit the
incorporation of haem into Hz (Chou et al., 1980; Egan et al., 1994;
Bray et al., 1998), the glutathione-mediated degradation of haem
(Ginsburg et al., 1998), and the peroxidative decomposition of
haem (Loria et al., 1999). It is believed that treatment of parasites
with CQ results in a build-up of haem and CQ–haem complexes
that are toxic to the parasite (Fitch, 2004). The precise molecular
basis of CQ-induced toxicity remains to be elucidated.
It has been postulated that a CQ-mediated build-up of haem
and CQ–haem complexes in the parasite may generate oxidative
stress by enhancing the toxicity of the ROS generated in the DV
during Hb degradation, and that this might cause or contribute
to parasite death (de Almeida Ribeiro et al., 1997; Loria et al.,
1999; Becker et al., 2004). However, it has also been suggested that
inhibition of the (iron-releasing) process of glutathione-mediated
haem degradation by CQ might lower oxidative stress in the para-
site (Ginsburg et al., 1998).
Experimental evidence in favour of CQ giving rise to oxidative
stress comes from Radfar et al. (2008), who showed that a 6 h
treatment of erythrocytes infected with CQR Dd2 parasites with
CQ at its 50% inhibitory concentration (IC50) led to an increase in
the degree of oxidation of parasite proteins. The number of parasite
proteins that were oxidised was also increased by CQ treatment
(Radfar et al., 2008). Another study found that adding a sub-inhib-
itory concentration of CQ (that reduced parasite proliferation by
610%) to parasites that were also exposed to sub-inhibitory con-
centrations of oxidative stress inducers (lactoperoxidase, glucose
oxidase and H2O2), resulted in combinations that inhibited parasite
growth by >25% (Malhotra et al., 1990). However, it was not clear
whether such combinations were additive or synergistic, thus ren-
dering the data difﬁcult to interpret.
Evidence against the hypothesis that CQ causes oxidative stress
comes from Atamna et al. (1994), who reported that the activity of
the pentose phosphate pathway (which generates NADPH, the
source of reducing equivalents for the glutathione- and thioredoxin
(Trx)-based antioxidant defence systems) was decreased in in-
fected erythrocytes and (to a lesser extent) isolated parasites after
a 30 min incubation with CQ, albeit at a supra-pharmacological
concentration (5 lM). In another study aimed at testing whether
CQ acts through oxidative stress, parasite cultures were grown in
an atmosphere comprised of 2% CO (which has a much higher
afﬁnity for Hb than O2), 5% CO2 and 93% N2; parasite susceptibility
to CQ was then assessed (Monti et al., 2002). Under these condi-
tions, carboxyHb rather than oxyHb would be digested in the par-
asite’s DV, and activated oxygen species should not form in the
process. It was found that parasites propagated normally under
these conditions and that their susceptibility to CQ was unchanged,
suggesting that the production of ROS is not central to the mecha-
nism by which CQ kills parasites (Monti et al., 2002).
Considering all the data, deﬁnitive evidence is still lacking on
whether CQ increases the oxidative stress experienced by the par-
asite and, if so, on whether this contributes to CQ’s parasiticidal
activity. The haem and CQ–haem complexes that accumulate upon
treatment with CQ could conceivably kill parasites through oxida-
tive stress and/or through non-oxidative means, for example by
accumulating in and consequently disrupting membranes
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interactions with proteins.
Even if CQ treatment does impose an additional oxidative bur-
den, the parasite’s antioxidant defence mechanisms may be sufﬁ-
cient to negate it such that the parasite does not experience
increased stress. Indeed, it has been reported that the expression
of various parasite antioxidant genes can escalate rapidly in re-
sponse to exogenously applied oxidative stress, and is increased
in parasites grown in (antioxidant-defence-challenged) glucose-
6-phosphate dehydrogenase (G6PD)-deﬁcient erythrocytes
(Akide-Ndunge et al., 2009). Studies on the effect of CQ treatment
on the P. falciparum proteome (Prieto et al., 2008) and transcrip-
tome (Gunasekera et al., 2003, 2007) did not uncover clear evi-
dence for an up-regulation of antioxidant defence systems.
However, a recent study focusing speciﬁcally on antioxidant de-
fence genes reported an up-regulation of certain transcripts,
including that for pfmrp, after CQ treatment (2 h at the IC50 concen-
tration) in both CQS (3D7) and CQR (Dd2) parasites (Nogueira et al.,
2010).
Recently Fu et al. (2010) described the application of a ﬂuores-
cent ROS reporter [5-(and 6)-chloromethyl-20,70-dichlorodihydro-
ﬂuorescein diacetate acetyl ester] to analyse oxidative stress in P.
falciparum-infected erythrocytes. It would be very informative in
further studies to see whether CQ treatment causes a detectable in-
crease in the ﬂuorescence signal, indicating generation of ROS.5. A link between the parasite’s glutathione system and
chloroquine response?
Multiple lines of evidence have linked the antioxidant tripep-
tide glutathione to the parasite’s response to CQ. Many of the
experiments involved were performed with the murine malaria
parasite Plasmodium berghei, and it should be noted that current
knowledge on mechanisms of CQ resistance reveal marked differ-
ences between murine parasite species and P. falciparum. The fol-
lowing sections summarise what is known about the glutathione
system in malaria parasites (focusing on P. falciparum), and exam-
ine the literature concerning the link between glutathione levels
and CQ response in both murine malaria parasites and P. falcipa-
rum. The focus of this review is the glutathione system of Plasmo-
dium as a potential parasite factor that modulates CQ response;
readers are referred to Becker et al. (2004) for a discussion of
how the antioxidant status of the host affects clinical outcome in
malaria.G
toxi
GSH
GSSG
N
GR
N
Reduction of
hydrogen or
lipid peroxides
L-glutamate + L-cysteine
γ-L-glutamyl-L-cysteine
γ-GCS
GS
glycine
Fig. 2. A schematic of the key components of the glutathione system in P. falciparum. G6P
glutathione reductase; GS, glutathione synthetase; GSH, reduced glutathione; GSSG,
resistance-associated protein.5.1. The glutathione system of antioxidant defence
Glutathione (c-L-glutamyl-L-cysteinyl-glycine; henceforth
abbreviated as GSH when referring to the reduced form, GSSG
when referring to oxidised glutathione disulphide, and not abbre-
viated when referring to both) plays a major role in cellular antiox-
idant defence. GSH functions as an electron donor and, through
this mechanism, plays a role both in the maintenance of protein
sulfhydryl moieties and in the reduction of hydrogen and lipid per-
oxides. GSH can also be conjugated to the electrophilic centres of
hydrophobic drugs and toxic metabolites through the action of glu-
tathione-S-transferase (GST) to form adducts that are then recogni-
sed for efﬂux by MRPs (Borst et al., 1999). Upon donating an
electron, the resulting oxidised glutathione molecule is most likely
to react with a second glutathione molecule (since glutathione is
present at millimolar concentrations in the cell) to form GSSG,
rather than reacting with another cellular component and causing
oxidative damage. GSSG is converted back to GSH by glutathione
reductase (GR) in a reaction that uses NADPH as the electron do-
nor. The resulting NADP+ can be reduced back to NADPH by two
enzymes in the pentose phosphate pathway: G6PD and 6-phos-
phogluconate dehydrogenase. Cells synthesise GSH in two ATP-
dependent steps. c-Glutamylcysteine synthetase (c-GCS) catalyses
the rate-limiting reaction between L-glutamate and L-cysteine to
produce c-L-glutamyl-L-cysteine. GSH synthetase (GS) then cataly-
ses the addition of glycine to form GSH.5.2. The Plasmodium falciparum glutathione system
Like most eukaryotic cells, malaria parasites have a functional
glutathione system for their antioxidant defence (Fig. 2). Different
cell types vary in their GSH:GSSG ratio but typically maintain it
above 10:1 (Dalle-Done et al., 2009). Atamna and Ginsburg (1997)
estimated a GSH:GSSG ratio of 285:1 for P. falciparum under normal
culture conditions. Many components of the P. falciparum glutathi-
one systemhave been identiﬁed and some have been studied exten-
sively. The P. falciparumGSH biosynthesis enzymes, PfGCS and PfGS,
have both been identiﬁed and their enzymatic activities character-
ised (Luersenet al., 1999, 2000;Meierjohannet al., 2002a,b). Neither
enzymehas been localised to date. The absence of an apparent signal
peptide inboth enzymes is consistentwith their being cytosolic, as is
the case inmammalian cells (Dalle-Done et al., 2009). The biochem-
ical and kinetic properties of P. falciparumGRhave also been studied
in depth, both with native PfGR isolated from parasites and withMRP
Parasite plasma
membrane
glutathione
conjugateST
c nucleophile
ADPH
ADP+
Pentose phosphate
pathway:
G6PD and 6-phosphogluconate
dehydrogenase 
D, glucose-6-phosphate dehydrogenase; c-GCS, c-glutamylcysteine synthetase; GR,
oxidised glutathione disulphide; GST, glutathione-S-transferase; MRP, multidrug
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localised to both the cytosol and the apicoplast of the parasite (Kehr
et al., 2010). The crystal structures of PfGR and PfGST have been
solved (Fritz-Wolf et al., 2003; Sarma et al., 2003).
PfMRP (discussed above as a potential modulator of CQ resis-
tance) is present on the plasma membrane of the intra-erythro-
cytic P. falciparum parasite (Klokouzas et al., 2004; Raj et al.,
2009). Erythrocytes infected with parasites in which the gene
encoding PfMRP was disrupted were found to accumulate more
radiolabelled GSH from the extracellular medium, consistent with
an impairment of glutathione efﬂux from the parasite (Raj et al.,
2009). Knockout parasites were also rendered more susceptible
to multiple antimalarial drugs, including CQ. This led the authors
to propose that PfMRP transports glutathione and various drugs
out of the cell, possibly as glutathione-drug adducts. However, Ata-
mna and Ginsburg (1997) had previously reported that there is no
pathway in the parasite plasma membrane for the import of exter-
nal GSH. Given the short time-scale of the GSH uptake experiments
(with time points of <10 min showing a difference between knock-
out and wild-type parasites), the results of Raj et al. (2009) can
probably not be explained by endocytic uptake of exogenous
GSH. Perhaps the increased uptake of GSH seen by Raj et al.
(2009) was into the host cell compartment and not the parasite.
Further studies are required to resolve this issue.
No other parasite proteins have been implicated in glutathione
transport to date and it is not known how the parasite’s glutathi-
one is distributed among its different compartments. Presumably
host cell glutathione is endocytosed by the parasite along with
Hb; whether it would be susceptible to degradation by peptidases
in the DV is not clear.
The parasite does not appear to possess a classical GSH peroxi-
dase (an enzyme that catalyses the reduction of H2O2 and lipid per-
oxides by GSH). An enzyme that was originally thought to be a GSH
peroxidase was subsequently shown to prefer the small redox-
active protein Trx as the electron donor and has since been re-clas-
siﬁed (Sztajer et al., 2001). However, it has been shown that PfGST
displays a GSH-dependent peroxidase activity with H2O2 and cer-
tain hydroperoxides (Harwaldt et al., 2002). A classical glutaredox-
in (PfGrx1) and a number of parasite glutaredoxin-like proteins
have also been identiﬁed (reviewed in Rahlfs et al., 2003). These
are small redox enzymes that use GSH as a cofactor to reduce var-
ious compounds and proteins. In a recent study, two of the glutare-
doxin-like proteins were localised to the cytosol, while one was
localised to the mitochondrion (Kehr et al., 2010).
5.3. Why would glutathione levels affect chloroquine response?
Two scenarios, which are not mutually exclusive, can be envis-
aged that might explain a link between parasite glutathione levels
and response to CQ:
(1) An increase in the glutathione concentration in the parasite
might reduce the accumulation of CQ by: (a) the glutathione
binding to haem (Atamna and Ginsburg, 1995) and thus pos-
sibly inhibiting the binding of CQ;(b) reducing the amount of
free haem available for CQ binding via glutathione-mediated
haem degradation (Ginsburg et al., 1998); and/or (c) increas-
ing the formation of CQ–glutathione adducts that are trans-
ported out of the parasite, thus allowing the parasite to
tolerate higher (external) CQ concentrations. It should be
noted that an HPLC analysis of cells treated with radiola-
belled CQ did not ﬁnd any evidence for the formation of
CQ adducts (Berger et al., 1995). However, the results of
Raj et al. (2009) and (for P. berghei) Dubois et al. (1995)
are consistent with the existence of CQ-adduct formation
and efﬂux.(2) An increase in the glutathione concentration in the parasite
might allow GSH to counter more of the oxidative damage
potentially caused by the CQ-mediated build-up of haem
and CQ–haem complexes, thus allowing the parasite to tol-
erate higher CQ concentrations.
5.4. Chloroquine and glutathione: studies in murine malaria parasites
In the ﬁrst study of its kind, it was found that CQR P. berghei par-
asites selected for by CQ pressure in vivo had much higher GSH lev-
els and greater GST activity than the CQS parasites fromwhich they
were derived (Dubois et al., 1995). GSH levels and GST activity
were assessed in parasites that were ‘isolated’ from their host
erythrocytes by ammonium chloride treatment. Furthermore,
buthionine sulfoximine (BSO), an inhibitor of c-GCS, decreased
parasite GSH levels and rendered CQR parasites more sensitive to
CQ in vivo (Dubois et al., 1995). A higher GST activity in CQR com-
pared to CQS P. berghei (as well as Plasmodium yoelii) parasites was
also reported in a subsequent study (Srivastava et al., 1999).
Following on from this, Platel et al. (1999) reported an inverse
relationship between Hz content on one hand, and glutathione
and GST levels (measured in isolated parasites) on the other, in P.
berghei strains exhibiting varying levels of CQ resistance. The two
most resistant lines provided an exception, as they differed mark-
edly in their CQ IC50 values and Hz contents, yet displayed similar
glutathione levels and GST activities. It should be noted that a
reduction in Hz formation is a feature of CQ resistance in P. berghei
but not in P. falciparum (Gligorijevic et al., 2006). The treatment of
mice infected with CQR P. berghei with BSO, which was conﬁrmed
in this study to lower parasite glutathione levels, led to a marked
increase in Hz levels. The authors proposed that GSH can detoxify
haem in the DV in CQR P. berghei parasites, thereby preventing its
incorporation into Hz and decreasing the potency of CQ (Platel
et al., 1999).
Platel et al. (1999) also noted that CQ resistance in P. berghei
was associated with an increased preference for reticulocytes, a
ﬁnding not observed in P. falciparum. The authors examined retic-
ulocyte glutathione levels and GST activity and found that both
were much higher than in mature erythrocytes. Notably, CQS par-
asites that had invaded reticulocytes were found to have higher
glutathione levels and GST activity (as assessed in parasites iso-
lated from their host cells) as compared with CQS parasites that
had invaded mature erythrocytes. This was accompanied by a
reduction in both Hz formation and susceptibility to CQ. This is
consistent with an earlier report of superior CQ potency against
P. berghei parasites growing in mature erythrocytes compared to
those growing in reticulocytes (Dei-Cas et al., 1984), and suggests
that the uptake of glutathione from reticulocytes may make a sub-
stantial contribution to parasite glutathione levels and to the
detoxiﬁcation of haem in the DV. The shift in host cell preference
is therefore likely to contribute to the observed correlation be-
tween CQ response and parasite glutathione levels in P. berghei.
A subsequent study found that mice infected with P. berghei or
Plasmodium vinckei petteri were more responsive to CQ treatment
when co-treated with drugs (acetaminophen and disulﬁram) that
have been shown to reduce glutathione levels or to decrease the
GSH:GSSG ratio in tissues (Deharo et al., 2003). These parasites
were somewhat less responsive to CQ when treated with N-acetyl-
cysteine (NAC) (Deharo et al., 2003). NAC is converted by the cell to
L-cysteine (the least available of the glutathione-component amino
acids in at least some cell types), and might be expected to increase
glutathione levels in Plasmodium. NAC alone appeared to exacer-
bate rodent malaria infections, thus complicating the interpreta-
tion of the CQ plus NAC data. Furthermore, the authors observed
no major changes in glutathione levels in blood samples taken
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vating compounds (Deharo et al., 2003).
In another study with P. berghei, it was reported that a CQR line
selected for by CQ pressure showed a 6-fold increase in the level of
mRNA encoding c-GCS compared to the CQS parental line (Perez-
Rosado et al., 2002). No differences in pbc-gcs sequence or copy
number were observed. Glutathione levels were not measured
but might be expected to increase upon overexpression of the
rate-limiting enzyme in GSH synthesis, again speaking to a link be-
tween elevated glutathione levels and CQ resistance in P. berghei.
Safeukui et al. (2004) also reported that two CQR lines of P. berg-
hei had higher GSH levels (as measured in saponin-isolated para-
sites) than a CQS line. However, the more resistant of the two
CQR lines (which had been selected with a higher CQ concentra-
tion) did not have a higher GSH level than the other CQR line. In
this study G6PD activity was found to be greater in the CQR para-
sites than in the CQS parasites. Dehydroepiandrosterone sulphate
(DHEAS), an inhibitor of G6PD, was found to decrease G6PD activ-
ity and the GSH:GSSG ratio in CQR parasites, and rendered them
more susceptible to CQ (Safeukui et al., 2004).
Taken together these studies provide strong evidence that glu-
tathione levels modulate CQ response in P. berghei. In a surprising
development, it was recently reported that the gene encoding c-
GCS (pbc-gcs) can be disrupted in P. berghei parasites and is there-
fore not essential during the asexual blood stages (Vega-Rodriguez
et al., 2009). However, pbc-gcs was found to be essential for para-
site development inside the mosquito. The disruption of pbc-gcs
led to a minor defect in the rate of proliferation of asexual blood
stage parasites and a marked reduction, but not complete deple-
tion, of parasite glutathione (Vega-Rodriguez et al., 2009). The
authors suggested that the glutathione found in the knockout par-
asites was obtained from the host erythrocyte by endocytosis. The
CQ susceptibility of the c-GCS knockout parasites has not been
reported.
GR can also be disrupted in P. berghei (Buchholz et al., 2010;
Pastrana-Mena et al., 2010), demonstrating that this protein is also
dispensable for asexual blood stage development. As was found for
c-GCS, GR was shown to be essential for oocyst development in the
mosquito. Glutathione levels in the GR knockout parasites were
not greatly reduced, and there was no effect of the gene disruption
on the growth of asexual blood-stage parasites (Buchholz et al.,
2010; Pastrana-Mena et al., 2010). CQ response was not tested.
There is evidence that other parasite proteins can reduce GSSG
(Kanzok et al., 2000; Becker et al., 2003), thereby potentially
explaining the non-essential nature of GR. Attempts to generate
parasites in which the genes encoding c-GCS and GR were both
disrupted were unsuccessful (Pastrana-Mena et al., 2010), suggest-
ing that at least one of the two proteins must be present to protect
the viability of asexual blood stage parasites.
Two studies have investigated whether the glutathione system
is involved in the CQ response of another murine parasite, Plasmo-
dium chabaudi. CQ resistance in this species has been linked to a
mutation in a deubiquitinating enzyme (Hunt et al., 2007). Ferreira
et al. (2004) reported that P. chabaudi strains that were CQS or had
varying degrees of CQ resistance showed no difference in the se-
quence or mRNA expression level of ﬁve genes of the glutathione
system. Furthermore, CQ treatment did not change the expression
levels of these genes (Ferreira et al., 2004). However, He et al.
(2009) reported that a CQR strain of P. chabaudi displayed higher
glutathione levels, higher GST activity and lower GR activity (all as-
sessed in isolated parasites) as compared to a CQS strain. Further-
more, three antiretroviral protease inhibitors that were shown to
potentiate the activity of CQ in the CQR strain of P. chabaudi were
found to decrease glutathione levels and GST activity (He et al.,
2009). One of these compounds (ritonavir) also rendered the CQS
strain more susceptible to CQ, and this compound (but not the oth-ers) caused a slight decrease in glutathione levels in this strain.
Thus, the latter study indicates that glutathione may also be linked
to CQ responses in P. chabaudi.
5.5. Chloroquine and glutathione: studies in Plasmodium falciparum
CQ resistance in P. falciparum differs markedly from CQ resis-
tance in P. berghei and P. chabaudi. In P. falciparum, CQ resistance
has not been linked with a decrease in Hz formation (Gligorijevic
et al., 2006) or a preferential invasion of reticulocytes. Rather,
resistance is associated with a marked reduction in CQ accumula-
tion (Fitch, 1970), which is thought to be mediated primarily by
mutant-PfCRT-mediated CQ efﬂux from the DV (Martin et al.,
2009). However, the degree of CQ resistance can differ among par-
asite lines that show no discernable difference in CQ accumulation
(Lehane et al., 2011).
Nogueira et al. (2010) reported that the glutathione system can
respond to CQ treatment and that this response can differ between
strains, as evidenced by the up-regulation of certain transcripts
(including pfmrp in the 3D7 and Dd2 strains and pfc-gcs and pfg6pd
in the 3D7 strain) after a 2 h exposure of the parasites to CQ, at a
concentration equivalent to the IC50 of the strain in question. But
does this response translate into an altered glutathione level, or
modulate CQ susceptibility?
Ginsburg et al. (1998) investigated the effects of various agents
that were reported to affect cellular glutathione levels on the
in vitro CQ response of the CQR FCR3 strain of P. falciparum.
Increasing glutathione levels in the infected erythrocyte by incu-
bating cultures with either 15 mM L-cysteine (which yielded a
2.5-fold increase after a 2 h treatment) or 10 mM NAC (2-fold
increase) was reported to increase resistance to CQ. The increases
in the CQ IC50 values, as determined in 42 h assays with the same
concentrations of L-cysteine and NAC, were 3-fold and 2.5-fold,
respectively. Conversely, a 2 h treatment with either 50 lM 1-
chloro-2,4-dinitrobenzene (CDNB, which conjugates GSH) or
6 mM BSO resulted in a decrease in the glutathione level to 70%
of control levels. Drug assays with lower concentrations of these
agents (4 lM CDNB and 3.5 mM BSO) resulted in a 30% reduction
in the CQ IC50 value (Ginsburg et al., 1998).
Different results were obtained in our recent investigations into
the effects of NAC and BSO (Lehane and Fidock, unpublished data).
The addition of 10 mM NAC to the medium caused a marked acid-
iﬁcation. When the pH was not adjusted back to its original value,
there was indeed a 2.2–3.1-fold increase in the CQ IC50 value
(tested in two CQR strains). However, when the pH was adjusted
(with NaOH) back to the same value as that of medium lacking
NAC, the increase in the CQ IC50 value in the presence of NAC
was signiﬁcantly less (1.3–1.5-fold). The pH of the medium is
known to affect CQ accumulation and susceptibility in P. falciparum
(Yayon et al., 1985). Furthermore, when tested at its approximate
IC50 value (in our hands 30 lM, not 3.5 mM), BSO (present
throughout 72 h drug assays) had no effect on parasite response
to CQ (tested in two CQS and two CQR strains of P. falciparum).
In another study, Meierjohann et al. (2002b) investigated the
sensitivity of a CQS P. falciparum strain, 3D7, and a CQR strain,
Dd2, to BSO, methylene blue (proposed to inhibit parasite GR),
and N,N1-bis(2-chloroethyl)-N-nitrosourea (BCNU; a compound
that inhibits GR activity and also depletes GSH by reacting with
it directly). 3D7 parasites were found to be more sensitive than
Dd2 parasites to growth inhibition by BSO, methylene blue, and
the oxidative stressor glucose oxidase, which catalyses the produc-
tion of D-gluconate and H2O2 from D-glucose. However, the strains
did not differ in their susceptibilities to BCNU (Meierjohann et al.,
2002b). It should be noted that PfGR inhibition is probably not the
mechanism by which methylene blue causes parasite death; GR
knockout P. berghei parasites show the same sensitivity to this drug
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for methylene blue are not necessarily related to differences in the
glutathione systems of 3D7 and Dd2.
Similarly, it is possible that BSO kills P. falciparum parasites
through a mechanism unrelated to its inhibition of the c-GCS en-
zyme. In Trypanosoma brucei, it was shown that adding extra
GSH to the medium did not prevent BSO-mediated parasite death,
but did prevent the death of parasites in which c-GCS expression
levels were reduced by RNA interference (Huynh et al., 2003). This
implies that BSO exerts its parasiticidal effect, at least against T.
brucei, via a mechanism independent of its effect on glutathione
concentration.
Luersen et al. (2000) investigated the activity of BSO against the
FCBR strain of P. falciparum. The compound was reported to inhibit
the proliferation of this strain with an IC50 value of 73 lM. At con-
centrations between 10 and 100 lM, BSO (after 24 h) was found to
inhibit c-GCS activity in both uninfected and infected erythrocytes.
This translated into a marked reduction in the glutathione level in
the infected erythrocytes but only a small reduction in the unin-
fected cells, consistent with there being a much higher turnover
of glutathione in infected erythrocytes. The authors found that
adding 1 mM GSH or GSH monoethyl ester to the medium de-
creased parasite susceptibility to BSO, but had no effect on GSH
levels in the infected erythrocytes. However, higher concentrations
of GSH and GSH monoethyl ester (15 mM) increased glutathione
levels in BSO-treated infected cells. It is not clear how GSH and
GSHmonoethyl ester were able to reduce the antiplasmodial activ-
ity of BSO at concentrations below those needed to increase gluta-
thione levels in the infected erythrocyte.
Meierjohann et al. (2002b) also reported that glutathione levels
in erythrocytes infected with CQR Dd2 parasites were slightly
higher than in those infected with CQS 3D7 parasites, although this
was not statistically signiﬁcant. However, Dd2 parasites isolated
from their host cells by streptolysin O treatment were found to
have signiﬁcantly more glutathione (134 nmol per 1010 cells) than
3D7 parasites isolated in the same way (67 nmol per 1010 cells). A
small difference such as this should be treated with caution, espe-
cially given that only one time point was investigated and the cells
were only synchronised once per week (Meierjohann et al., 2002b).
Of note, it has been shown that glutathione levels in erythrocytes
infected with 3D7 parasites ﬂuctuate somewhat during the course
of the 48 h asexual cycle (Olszewski et al., 2009).
An investigation of individual components of the glutathione
system in 3D7 parasites and Dd2 parasites also revealed some
differences between the strains. GR activity was found to be signif-
icantly higher in 3D7 parasites than in Dd2 parasites, despite there
being similar GR protein levels in the two strains (Meierjohann
et al., 2002b). This suggests that the GR enzymes in the two strains
may have different kinetic properties. Gilberger et al. (2000) had
previously reported different kinetic properties for GRs from differ-
ent strains, with the GR from K1 (a CQR strain) having a higher
catalytic efﬁciency than that from the CQS 3D7 strain. The GRs
from the two strains differed by three amino acids (Gilberger
et al., 2000). More recently, a study in which GR activity was exam-
ined in eight different P. falciparum strains (four CQS and four CQR)
revealed that while there were differences between strains, these
were unrelated to the CQ susceptibility of the strain (Sarma
et al., 2003).
Meierjohann et al. (2002b) also reported signiﬁcant differences
in c-GCS activity between Dd2 and 3D7 parasites, this time with
Dd2 parasites having the higher activity. The efﬂux of glutathione
was found to be comparable for Dd2- and 3D7-infected erythro-
cytes. Based on these investigations, it was proposed that Dd2 par-
asites are more dependent on GSH synthesis to maintain their GSH
levels than are 3D7 parasites, whereas in 3D7 parasites GSH levels
are primarily determined by GR activity. Although these results areinteresting, it must be remembered that 3D7 and Dd2 parasites
have distinct genetic backgrounds, and thus any differences in
their glutathione systems are not necessarily related to their differ-
ent CQ susceptibilities.
Raj et al. (2009) also reported that manipulating GSH levels can
inﬂuence CQ response. Addition of 2 mM GSH to the medium re-
duced CQ accumulation in the CQS 3D7 strain (by 48%), in the
CQR W2 strain (by 11%) and in the W2 PfMRP knockout strain
(by 30%). The addition of 2.5 mM GSH to the culture medium
was also reported to cause a decrease in parasite susceptibility to
CQ in all three strains (Raj et al., 2009). As mentioned above, these
results appear to be at odds with the ﬁnding by Atamna and
Ginsburg (1997) that GSH was not transported into the parasite
across the parasite plasma membrane. Experiments in the Fidock
laboratory, in which CQ drug assays were performed with four dif-
ferent strains of P. falciparum, revealed that the addition of 2 mM
GSH acidiﬁed the medium, and that adjustment back to the origi-
nal pH with NaOH nulliﬁed the small effect of GSH on CQ response
(Lehane and Fidock, unpublished data). Taken together, this sug-
gests that the pH, and consequently the protonation state of CQ,
may have been responsible for the reduction in CQ accumulation
and susceptibility observed by Raj et al. (2009) rather than a direct
GSH-mediated effect.
In their study on the impact of antiretroviral inhibitors on CQ
response, He et al. (2009) reported results for P. falciparum that
were analogous to those observed for P. chabaudi (discussed
above). The P. falciparum strains studied (3D7 and Dd2) were the
same two that were investigated in Meierjohann et al. (2002b).
Like Meierjohann et al., He et al. (2009) reported that glutathione
levels were higher, and GR activity lower, in Dd2 parasites com-
pared to 3D7 parasites. Three antiretroviral protease inhibitors that
were reported to sensitise the Dd2 strain to CQ were found to de-
crease glutathione levels and GST activity in isolated Dd2 parasites.
The most potent chemosensitiser, ritonavir, also decreased GR
activity and glutathione peroxidase activity in Dd2 parasites. This
agent also rendered 3D7 parasites somewhat more sensitive to
CQ and caused a small decrease in glutathione levels and GR
activity.
The putative association between GST activity and CQ response
(as seen in murine parasites and reported for P. falciparum by He
and colleagues) has been investigated in two other studies with
P. falciparum. Rojpibulstit et al. (2004) reported that isolated CQR
K1 parasites displayed higher GST activity than CQS T9/94 para-
sites. No kinetic differences were found, leading the authors to sug-
gest that there might be a difference in GST expression levels
between the strains (Rojpibulstit et al., 2004). However, a more
comprehensive analysis involving four CQS and four CQR strains
of P. falciparum found no association between GST activity and
CQ resistance (Harwaldt et al., 2002).
5.6. Chloroquine and glutathione: summary
Several studies with P. berghei have correlated high glutathione
levels with CQ resistance (Dubois et al., 1995; Platel et al., 1999;
Safeukui et al., 2004). In all cases a substantial (>5-fold) difference
was observed between the glutathione contents of isolated CQR
and CQS parasites, and similar values for the glutathione concen-
trations of CQS and CQR strains were obtained in the different
studies. As further evidence for the ability of glutathione to modu-
late CQ response in P. berghei, the c-GCS inhibitor BSO was shown
to lower glutathione levels and increase CQ susceptibility (Dubois
et al., 1995), while growth in glutathione-rich reticulocytes was
shown to elevate parasite glutathione levels and decrease CQ sus-
ceptibility (Platel et al., 1999).
In contrast, the case for the glutathione system’s involvement in
P. falciparum CQ resistance is less robust. Two studies, both with
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2–2.5-fold higher glutathione level in the (isolated) CQR parasites
compared to the CQS parasites (He et al., 2009; Meierjohann et al.,
2002b). However, there was a >30-fold difference in the glutathi-
one content estimates between the two studies; the reason for this
is not clear. Ginsburg et al. (1998) reported that glutathione levels
and the CQ IC50 value were lowered by 30% following 2 h expo-
sures of parasites to millimolar concentrations of BSO (concentra-
tions >45-fold higher than BSO IC50 values obtained by Luersen
et al. (2000) and Lehane and Fidock (unpublished)). NAC (Ginsburg
et al., 1998) and GSH (Raj et al., 2009) were reported to decrease
parasite susceptibility to CQ but this may have resulted from the
effects of these compounds on the pH of the medium (Lehane
and Fidock, unpublished data). Despite the lack of deﬁnitive evi-
dence to date, the idea that P. falciparum could bolster its glutathi-
one levels to enhance its resistance to CQ is certainly plausible,
especially in light of the ﬁndings for P. berghei.6. Other antioxidant defence mechanisms and chloroquine
response
In addition to the glutathione system, P. falciparum encodes the
components of a Trx system. This system comprises Trx (a small
protein that can provide reducing equivalents to peroxidases),
Trx reductase (TrxR, which regenerates the reduced form of Trx
from its oxidised form) and various Trx-dependent peroxidases
(Tpx) (Muller, 2004). Several components of the P. falciparum Trx
system were recently localised in blood-stage parasites (Kehr
et al., 2010). TrxR, which localises to the cytosol and the mitochon-
drion (Kehr et al., 2010), is essential for erythrocytic-stage P. falci-
parum (Krnajski et al., 2002), but is dispensable for the blood stages
of P. berghei (Buchholz et al., 2010). A recent study showed that P.
falciparum imports a host Trx-dependent peroxiredoxin (hPrx-2)
into its cytosol, and that this enzyme accounts for a signiﬁcant
fraction of Trx peroxidase activity in parasite extracts (Koncarevic
et al., 2009).
P. falciparum also possesses two superoxide dismutases (SODs)
(metalloproteins that catalyse the dismutation of O2 into H2O2
and O2). One of these (SOD-1) localises to the cytosol and the other
(SOD-2) localises to the mitochondrion of blood-stage parasites
(Gratepanche et al., 2002; Sienkiewicz et al., 2004). Furthermore,
the host cell SOD is taken up by the rodent parasite P. berghei with
Hb (Fairﬁeld et al., 1983). Whether SOD uptake from the host cell
contributes to the dismutation of O2 in the DV in P. falciparum is
not clear (Muller, 2004).
To the best of our knowledge, only two studies have considered
a possible link between any of these (non-glutathione-associated)
antioxidant proteins and CQ response. An analysis of changes in
protein abundance on treatment with CQ revealed that the amount
of the human Trx-dependent peroxiredoxin imported by the para-
site was increased in response to CQ pressure in both CQS (3D7 and
HB3) and CQR (K1 and Dd2) strains, by a factor of 1.6–4.5
(Koncarevic et al., 2009). Nogueira et al. (2010) reported an in-
crease in mRNA expression of pfFe-sod in 3D7 parasites, and of
pftrxR and pftpx1 in Dd2 parasites, on exposure to IC50 levels of
CQ for 2 h. Whether the changes in mRNA/protein abundance
reported in the above studies translate into an increase in antiox-
idant power that enables a parasite to withstand higher concentra-
tions of CQ remains to be seen.7. Chloroquine action and resistance in Plasmodium vivax
Although widespread, Plasmodium vivax malaria, sometimes re-
ferred to as ‘benign’, has long been considered to be of secondary
importance compared to P. falciparum malaria because it is lesslethal. Nonetheless, there are an increasing number of reports of
P. vivax malaria giving rise to severe symptoms (Baird, 2007; Tjitra
et al., 2008) and its importance has clearly been underappreciated.
CQ survived as a ﬁrst-line therapy for the treatment of P. vivax
malaria well beyond its survival as an effective therapy for P. falci-
parum malaria, and it continues to be widely used. Nevertheless,
following on from the ﬁrst reports of CQR P. vivax in 1989 there
are a growing number of reports of cases of CQR P. vivax malaria
from South and Southeast Asia, as well as from South America
(Suwanarusk et al., 2007).
The ﬁnding that in P. vivax, unlike in P. falciparum, the mature
trophozoite-stage (Hb-digesting) form of the parasite is markedly
less sensitive to CQ than younger, ring-stage parasites (Sharrock
et al., 2008) raises the possibility that the mechanism by which
CQ kills P. vivaxmight differ from that bywhich it kills P. falciparum.
Similarly, the lack of a clear association between CQ resistance in P.
vivax and mutations in the P. vivax orthologue of the CRT protein
(Nomura et al., 2001; Suwanarusk et al., 2007; Barnadas et al.,
2008; Orjuela-Sanchez et al., 2009) points to the mechanism of
CQ resistance in P. vivax being different from that in P. falciparum.
The extent to which the redox system of the parasite might play
a role in the mechanism of action of, or resistance to, CQ in P. vivax
has not, to our knowledge, been investigated. Nor is it clear to what
extent the intracellular parasite might draw on the redox machin-
ery of its host cell. P. vivax, unlike P. falciparum, has a strong pref-
erence (if not an absolute requirement) for reticulocytes over the
mature erythrocyte. Whether, as has been proposed for the reticu-
locyte-preferring murine parasite P. berghei (Platel et al., 1999), the
intra-reticulocytic P. vivax parasite might draw on the redox sys-
tem of its host cell to bolster its own oxidative defences, and
whether this might play a role in CQ resistance in this parasite,
would seem a worthwhile area for study.
8. Conclusion
Deﬁnitive studies are still required to test the hypothesis that
oxidative stress is the lethal consequence of CQ’s binding to haem
in the malaria parasite. Of note, a recent study with a ﬂuorescent
ROS reporter provided evidence that artemisinins generate oxida-
tive stress within P. falciparum (Klonis et al., 2011). Similar exper-
iments may well provide important insights into the mode of
action of CQ. In P. berghei, it appears that CQ resistance is associ-
ated with higher intra-parasite glutathione levels, which serve to
degrade CQ’s haem target. This association may be explained in
part by the preferential invasion of glutathione-rich reticulocytes
by CQR parasites. In P. falciparum, a link between glutathione levels
and CQ response is not ﬁrmly established, and further work is re-
quired to determine whether the parasite’s redox system plays a
role in determining the CQ resistance levels of PfCRTK76T-bearing
parasites. One approach would be to analyse glutathione levels at
different time points among a series of carefully synchronised
strains with varying CQ susceptibilities. Furthermore, it would be
informative to determine whether c-GCS is dispensable for the P.
falciparum blood stages. If blood-stage P. falciparum parasites in
which the c-gcs gene is disrupted prove to be viable and show de-
creased glutathione levels (as seen for P. berghei), then CQ drug as-
says on the knockout parasites would provide important insights
into any role for glutathione in determining the CQ response of
the human parasite. Whether the redox system of the parasite, or
host cell, might play a role in the more recent phenomenon of
CQ resistance in P. vivax remains an open question.
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